Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 29

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 29
---
 otherwise indicates, the terms ‘‘we,” “our,” “us,” or “the Company” refer to Telomir Pharmaceuticals, Inc., a Florida corporation, and its subsidiaries taken as a whole.

Overview

Telomir-1
is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative
stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help
protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s
disease (a genetic disorder leading to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type
2 Diabetes, cancer, and Alzheimer’s disease. Oxidative stress also plays a critical role in the propagation and severity of viral
infections like bird flu, where the virus triggers an imbalance between increased production of reactive oxygen species (ROS) and reduced
antioxidant host responses that leads to increased redox stress, a process which ultimately excessive weakens immune defenses, increases
inflammation, and enables enhanced viral replication. By reversing oxidative stress, Telomir-1 may help strengthen immune resilience
and reduce disease severity, offering broad therapeutic potential across both age-related and infectious diseases.

Telomeres are repetitive DNA sequences at the end of chromosomes that protect the chromosomes from becoming frayed or tangled. Each time a cell divides, the telomeres become slightly shorter, and eventually they become so short that the cell can no longer divide, with the result being that the cell dies. Effectively, telomeres protect the ends of our chromosomes by forming a cap, much like the plastic tip on shoelaces, thereby allowing the chromosome to be replaced properly during cell division. If demonstrated by future clinical trials and approved by the U.S. Food and Drug Administration, or FDA, we believe Telomir-1 may protect variable cells by elongating and stimulating the telomeres to sustain self-renewal and longevity.

Based on our preclinical studies, we have gathered experimental evidence suggesting that Telomir-1 may act as a regulator of essential metal ions such as iron, zinc, and copper. While these trace elements are critical for various physiological functions, imbalances—whether due to excess or deficiency —can drive oxidative stress, leading to cellular damage, telomere shortening, and accelerated aging. This oxidative burden is